Jennifer Hurd, MD
Internal Medicine · Lewes, DENPI 1932333465
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.0% of the total across 224 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 13.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $849 and has fallen 81.7% since, to $155 in 2025.
Across 224 payments — averaging $16.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$472
- AbbVie$331
- Lilly USA, LLC$315
- Astellas Pharma US Inc$263
- GSK$251
- Amgen$232
- plus $2K from 24 others
What the payments were for
- Food & beverage$3,48696%
- Education$1454%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 35 | $472 |
| AbbVie(2 entities) | 20 | $331 |
| Lilly USA, LLC | 19 | $315 |
| Astellas Pharma US Inc | 9 | $263 |
| GSK | 15 | $251 |
| Amgen(2 entities) | 14 | $232 |
| AstraZeneca | 15 | $216 |
| Daiichi Sankyo Inc. | 13 | $210 |
| Boehringer Ingelheim | 14 | $207 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $172 |
| Pfizer | 11 | $171 |
| Exact Sciences | 6 | $114 |
| Amarin Pharma, Inc. | 6 | $94 |
| Kowa Pharmaceuticals America, Inc. | 5 | $71 |
| Bayer | 4 | $65 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $53 |
| Sanofi-aventis U.S. LLC | 3 | $49 |
| Xeris Pharmaceuticals, Inc. | 2 | $47 |
| Sumitomo Pharma America, Inc. | 2 | $45 |
| Scilex Pharmaceuticals Inc. | 3 | $42 |
| Lundbeck LLC | 2 | $34 |
| Corcept Therapeutics | 1 | $29 |
| Merck | 2 | $25 |
| Abbott | 1 | $25 |
| Dexcom, Inc. | 1 | $22 |
| Linus Health, Inc. | 1 | $19 |
| Novartis | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Medtronic | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
How this compares
$3,631 in reported general payments places this provider in the 85th percentile of 477 internal medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 144 | $275,101 |
| JardianceEmpagliflozin | 78 | $132,120 |
| EliquisApixaban | 85 | $99,092 |
| JanuviaSitagliptin Phosphate | 65 | $95,791 |
| FarxigaDapagliflozin Propanediol | 45 | $64,069 |
| MounjaroTirzepatide | 34 | $62,702 |
| TrulicityDulaglutide | 39 | $60,666 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $55,091 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 43 | $42,998 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 22 | $41,941 |
| XareltoRivaroxaban | 39 | $41,432 |
| RybelsusSemaglutide | 17 | $40,433 |
| LinzessLinaclotide | 26 | $34,994 |
| JanumetSitagliptin Phos/Metformin Hcl | 33 | $34,188 |
| GemtesaVibegron | 26 | $25,160 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus | $472 | $357,475183 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $207 | $146,06292 claims |
| MerckJanuvia, Janumet | $25 | $129,97998 claims |
| Lilly USA, LLCMounjaro, Trulicity | $315 | $123,36873 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $251 | $118,016110 claims |
| PfizerEliquis | $171 | $99,09285 claims |
| AstraZenecaFarxiga | $216 | $64,06945 claims |
| AbbVieLinzess, Vraylar, Synthroid | $331 | $63,094239 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $45 | $25,16026 claims |
| NovartisEntresto | $16 | $23,21516 claims |
| Astellas Pharma US IncMyrbetriq | $263 | $22,59923 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $49 | $17,81713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 477 internal medicine providers in Delaware.
Other internal medicine in Lewes
- Bhaskar PalekarLewes$22K
- Irene ViolaLewes$15K
- Malick IslamLewes$11K
- Charles StanislavLewes$5K
- Preachess VellahLewes$3K
- Monique YostLewes$3K
- Seth IvinsNewark$384K
- Beshara HelouGeorgetown$143K
- Tabassum SalamNewark$62K
- Fabricio AlarconGeorgetown$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.